Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.

Abstract

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.

Keywords: MERS-CoV; SARS-CoV; SARS-CoV-2; human coronaviruses; neutralizing antibodies.

MeSH terms

  • Antibodies, Neutralizing / immunology
  • Antibodies, Neutralizing / therapeutic use*
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use*
  • Betacoronavirus / immunology*
  • COVID-19
  • Coronavirus / immunology*
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / therapy
  • Humans
  • Pandemics / prevention & control
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / prevention & control
  • Pneumonia, Viral / therapy
  • Research / trends
  • SARS-CoV-2

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral